Suchergebnisse - "Papp, Kim A"

PubPharm (331)

1

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis : A randomized, double-blinded, vehicle-controlled, phase 3 trial

enthalten in: Journal of the American Academy of Dermatology | 2024

von Blauvelt, A. | Draelos, Z. | Stein Gold, L. | +18

2

Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis : a 52-week, phase 2, open-label trial

enthalten in: Journal of the American Academy of Dermatology | 2024

von Stein Gold, L. | Adam, D. | Albrecht, L. | +18

3

Deucravacitinib in moderate-to-severe plaque psoriasis : Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)

enthalten in: Journal of the European Academy of Dermatology and Venereology : JEADV | 2024

von Strober, B. | Blauvelt, A. | Warren, R. | +12

4

Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis : Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial

enthalten in: Journal of the American Academy of Dermatology | 2024

von Merola, J. | Parish, L. | Guenther, L. | +10

5

Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis : a post-hoc analysis of final safety data from 25 randomized clinical trials

enthalten in: Arthritis research & therapy | 2024

von Deodhar, A. | Blauvelt, A. | Lebwohl, M. | +13

6

Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials

enthalten in: Arthritis Research & Therapy | 2024

von Deodhar, A. | Blauvelt, A. | Lebwohl, M. | +13

7

Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary : A Secondary Analysis of a Randomized Clinical Trial

enthalten in: JAMA dermatology | 2024

von Papp, K. | Gordon, K. | Strober, B. | +9

8

Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis : 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study

enthalten in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2024

von Papp, K. | Lebwohl, M. | Thaçi, D. | +20

9

Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis : Results from a phase 2b, randomized, controlled trial

enthalten in: Journal of the European Academy of Dermatology and Venereology : JEADV | 2023

von Guttman-Yassky, E. | Silverberg, J. | Thaçi, D. | +11

10

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis : Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up

enthalten in: Journal of the American Academy of Dermatology | 2023

von Papp, K. | Blauvelt, A. | Puig, L. | +14

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[34]